Annovis Bio, Inc. (ANVS)
Upgrades & Downgrades
Latest ANVS news
Alzheimer's Disease Drug Development: Another Lost Year
5 December 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of...
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
1 December 2023
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
13 October 2023
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any ad...
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
12 October 2023
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's ...
3 Biotech Stocks to Buy Before Drug Trials End
28 July 2023
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
New Strong Buy Stocks for April 21st
21 April 2023
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
New Strong Buy Stocks for April 18th
18 April 2023
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
Annovis: Making Sense Of The Interim Analysis
12 April 2023
Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months t...
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?
7 April 2023
Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Annovis And Buntanetap: Asymmetric Risk/Reward Ahead Of Parkinson's Data Readout
30 March 2023
Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Parkinson's data to be presented today (3/30/23) at ...